A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia

Trial Profile

A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Tisagenlecleucel-T (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 13 Feb 2017 Planned primary completion date changed from 1 Jun 2017 to 11 Jan 2017.
    • 13 Feb 2017 Status changed from not yet recruiting to withdrawn prior to enrolment.
    • 30 Sep 2015 Status changed from recruiting to not yet recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top